Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL
Yes Virginia, There Is a Santa Claus Rally
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's Why
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023
Wall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to Trade
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
What Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now?
Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect?
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Call Transcript
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
Should You Buy Gracell Biotechnologies (GRCL) Ahead of Earnings?
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program
Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences
Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Gracell Biotechnologies to Report Third Quarter 2023 Financials on Monday, November 13, 2023
Gracell Biotechnologies Reports Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent Complete Response Rate
Gracell Biotechnologies Doses First Patient in Phase 1b/2 Clinical Trial in U.S. Evaluating GC012F for Treatment of Relapsed/Refractory Multiple Myeloma
Gracell Biotechnologies' CEO Dr. William Cao Named to Prestigious PharmaVoice 100, Honoring Most Inspiring Life Science Leaders
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Call Transcript
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
Why Shares of Gracell Biotechnologies Are Rising Monday
Penny Stocks To Buy? 5 To Watch With Big News This Week
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors
Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
Gracell Biotechnologies to Participate in BTIG Virtual Biotechnology Conference
Gracell Biotechnologies (GRCL) Surges 62% in a Week: Here's Why
Why Shares of Gracell Biotechnologies Jumped Tuesday
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
Gracell Biotechnologies to Report First Quarter 2023 Financials on Monday, May 15, 2023
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting
Orbimed Advisors Now Owns 11.2% of Gracell Biotechnologies
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
Gracell Biotechnologies Inc. (GRCL) Q4 2022 Earnings Call Transcript
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences